Lung Oncology CRO
Support for lung cancer studies that demand more than standard oncology trial execution
Lung cancer trials often involve biomarker complexity, advanced-stage disease burden, intense competition for enrollment, and rapidly evolving standards of care. Worldwide helps sponsors navigate these challenges with lung-specific operational expertise, realistic feasibility planning, and global execution informed by local clinical practice.
Tell us about your study
We’ll connect you with the right oncology clinical
development team.
Your Lung Oncology Trial Challenges
Why Lung Oncology Trials Become Difficult Quickly
Lung cancer trials can quickly become more operationally demanding than sponsors expect. Restrictive eligibility criteria, biomarker-defined non-small cell lung cancer (NSCLC) populations, and aggressive timelines can make it challenging to identify sufficient patients to meet enrollment targets. Advanced-stage disease can increase the risk of patient dropout and adverse events, while NSCLC and small cell lung cancer (SCLC) require distinct treatment pathways and study considerations. At the same time, evolving standards of care and shifting competitive landscapes can impact protocol viability, country strategy, and site performance over time. Worldwide helps sponsors navigate these realities through biomarker-informed feasibility, global planning, and support designed to maintain enrollment momentum, safety oversight, and data quality throughout the study.
Finding the Right Patients Takes More Than Reach
In lung oncology, aggressive timelines are often misaligned with the actual availability of eligible patients. Worldwide helps sponsors plan early using insights into biomarker prevalence, treatment setting, and real-world site-level patient access.
Screening Burden Can Slow Studies Down
Biomarker testing, restrictive eligibility criteria, and high screen failure rates can increase costs and place additional strain on sites. Worldwide helps sponsors account for these challenges through informed feasibility, site selection, and enrollment planning before they disrupt execution.
Disease Burden Affects Safety & Retention
Advanced-stage lung cancer populations often present higher rates of adverse events, faster disease progression, and greater dropout risk. Worldwide supports sponsors with operational strategies that enhance monitoring, continuity, and overall study oversight.
Protocol Pressure Continues After Startup
Evolving oncology, evolving standards of care and competitor activity can force mid-study adjustments, adding complexity across sites and regions. Worldwide helps sponsors manage these changes while maintaining focus on timelines, data quality, and study objectives.
Partnership & Approach
Operational Judgment for a Fast-Moving Indication
Lung cancer studies often require critical decisions early on, especially around feasibility, site strategy, safety considerations, and scalability. Worldwide partners with sponsors to apply indication-specific operational insights, helping ensure plans remain realistic and execution stays aligned as the study complexity increases.
Studies in the Past 5 years
Patients Enrolled
Unique Sites
Why Worldwide
What Makes Worldwide the Right Lung Cancer Trial Fit?
Worldwide combines lung cancer-specific operational expertise, global planning capabilities, and development experience to support sponsors in a highly competitive and clinically complex indication.
Built for Lung Cancer Trial Complexity
Lung cancer studies can span NSCLC, SCLC, mutation-defined populations, and multiple lines of therapy, each bringing distinct operational challenges. Worldwide helps sponsors plan and execute with a practical understanding of how these differences shape feasibility and study conduct.
Realistic Biomarker Planning
In biomarker-driven NSCLC studies, screening assumptions play a critical role in timeline success. Worldwide helps sponsors account for biomarker prevalence, testing access, tissue requirements, and expected screen-to-enroll ratios, ensuring enrollment plans reflect current trial realities.
Breadth Across Development
Worldwide supports lung cancer drug development from first-in-human through Phase III. This continuity allows sponsors to carry operational insights forward as programs transition from early planning to larger, more demanding global studies.
Global Strategy Where It Matters
Lung cancer trials often require a broad geographic footprint to reach the right patient populations and maintain enrollment. Worldwide helps sponsors align country selection, site strategy, and enrollment potential within a competitive global landscape.
Countries Across
Key Regions
Focused on the Right Risks
In lung cancer clinical trials, enrollment, safety, and data quality are closely interconnected. Worldwide helps sponsors address these risks in an integrated way, with support tailored to advanced-stage patient populations, increased oversight requirements, and the operational pressures that can build as studies progress.
Services & Capabilities
Comprehensive Oncology CRO Services
- Protocol Design and Clinical Development Planning
- Regulatory Consulting and Global Submissions
- Global Project Management
- Feasibility Analysis and Site Selection Strategy
- Site Initiation and Study Start-up
- Patient Enrollment
- Dose Escalation, Optimization and Cohort Management
- Site Monitoring and Management
- Data Management
- Clinical Data Analytics and Review
- Clinical Science
- Biostatistics
- Medical Monitoring
- Safety / Pharmacovigilance
- Medical Writing
Biomarker Feasibility & Enrollment
Worldwide helps sponsors build lung cancer enrollment strategies grounded in biomarker prevalence, eligibility criteria, site testing capabilities, and screen failure risk, ensuring feasibility assumptions are realistic from the start.
Global Site & Country Strategy
For lung cancer studies facing competitive enrollment pressure, Worldwide supports identification of countries, sites, and investigators best positioned to enable efficient startup and patient access across a broader global landscape.
Support Across NSCLC & SCLC
Worldwide supports studies in both NSCLC and SCLC, including mutation-defined NSCLC populations, with operational planning that reflects the differing treatment pathways, patient characteristics, and study requirements.
Safety & Data Oversight
In later-stage or heavily pretreated patient populations, Worldwide helps sponsors enhance monitoring and implement centralized imaging and data review strategies to support consistent oversight and high-quality data across the study.
What Our Clients Say
“Worldwide offers the right combination of size, flexibility, experience and focus on building a stronger sponsor/CRO relationship.”
North American Small Biopharma Company
FAQ & Insights
What Sponsors Need to Know
Lung cancer trials often bring multiple challenges together. Sponsors may need to address both NSCLC and SCLC populations, biomarker-defined NSCLC eligibility, advanced-stage disease, and a highly competitive environment for sites and patients. Together these factors can influence feasibility, increase screening burden, complicate safety management, and drive the need for earlier global expansion.
Worldwide approaches enrollment with a strong focus on feasibility from the start. This includes careful evaluation of biomarker-defined populations, country and site strategy, investigator capabilities, and the competitive landscape, enabling sponsors to make more informed enrollment decisions upfront. This planning helps minimize delays and supports effective global execution when needed.
Worldwide supports lung cancer studies that depend on genetic profiling and biomarker selection, particularly in NSCLC targeted therapies and immuno-oncology development. This experience is critical in a setting where mutation status, tissue availability, testing turnaround times, and screening logistics can directly impact enrollment timelines and screen failure rates.
Later-stage lung cancer studies can bring higher adverse event rates, increased patient dropout risk, and greater endpoint variability, especially in advanced-stage disease populations. Worldwide addresses these challenges with enhanced safety oversight, centralized imaging, and robust data review strategies designed to support consistent monitoring and high-quality data throughout the study.
Yes. Worldwide supports lung cancer drug development from first-in-human through Phase III with experience spanning targeted therapies, IO, ADCs, cell therapies, bispecifics, and combination approaches. This breadth enables sponsors to maintain continuity as programs transition from early development to larger, more operationally demanding studies.
Biomarker testing can significantly influence both. Factors such as tissue availability, testing turnaround times, re-biopsy requirements, and biomarker-defined eligibility may slow enrollment and increase screen failures if not planned carefully. Worldwide helps sponsors address these considerations early within feasibility, site selection, and enrollment strategy.
The answer depends on the target patient population, biomarker requirements, line of therapy, and competitive landscape. In many cases, lung oncology trials require a broader geographic footprint than sponsors initially anticipate. Worldwide brings lung cancer experience across 455+ sites enrolling 7,800+ patients in 28 countries spanning North America, Europe, Asia-Pacific, Latin America, Africa, and selected Eurasian regions. This reach helps support country and site planning aligned with real enrollment potential.
In lung cancer, protocols need to remain viable as standards of care and competitive activity can shift quickly. Sponsors must consider eligibility criteria, endpoints, and operational assumptions that can adapt over time as the landscape changes. Worldwide works with sponsors to anticipate these risks early and design protocol strategies, country footprints, and enrollment plans that remain resilient as development progresses.
Insights
Explore Our Lung Oncology Insights
Oncology Expertise
Looking for Other Oncology Specializations?
See what Worldwide Clinical Trials can do for you.
Your study has unique goals, risks, and decisions ahead. Tell us a little about your needs, and our team will connect you with the right Worldwide experts to discuss how our scientific, medical, and operational support can help move your program forward with confidence.
